NM_000329.3(RPE65):c.118G>A is a missense variant predicted to replace glycine with serine at position 40. This variant is present in gnomAD v.2.1.1 at a GrpMax allele frequency of 0.00006, with 2 alleles/24966 total alleles in the African/African-American population, which is lower than the ClinGen LCA / eoRD VCEP PM2_Supporting threshold of <0.0002 (PM2_Supporting). The computational predictor REVEL gives a score of 0.984, which is above the ClinGen LCA / eoRD VCEP threshold of ≥ 0.773 and predicts a damaging effect on RPE65 function (PP3_Moderate). The variant exhibited <2 % enzymatic activity in a retinoid isomerase assay relative to the wild-type control, which is lower than the ClinGen LCA / eoRD VCEP PS3_Supporting threshold of <10% activity, indicating that it triggers a severe defect in protein function (PS3_Supporting, PMID: 16150724 ). This variant has been reported in at least 2 unrelated probands with early-onset severe retinal dystrophy who were homozygous for the variant (1 pt, PMID: 25257057, PMID: 33608557). This variant has also been reported in at least 3 probands with early-onset severe retinal dystrophy who were compound heterozygous with either the NM_000329.3(RPE65):c.544C>T (p.His182Tyr) variant confirmed in trans (1 pt, PMID: 9501220, PMID: 11462243), the c.11+5G>A variant suspected in trans (0.5 pts, PMID: 18441371), or the p.Arg91Gln variant suspected in trans (0.5 pts, PMID: 19117922), all of which were previously classified pathogenic by the ClinGen LCA / eoRD VCEP (total 3 pts, PM3_Strong). The variant has been reported to segregate with childhood-onset severe retinal dystrophy through the proband plus 1 similarly affected relative, with the variant present in the compound heterozygous state (PMID: 9501220, PP1). At least one proband harboring this variant exhibits a phenotype including diagnosis of Leber congenital amaurosis (0.5 pts), absent or severely reduced rod ERG (0.5 pts), decreased central visual acuity (1 pt), and significant improvement of visual function by FST after gene-specific gene therapy (8 pts), which together are highly specific for RPE65-related recessive retinopathy (total 10 pts, PMID: 21911650, PP4_Moderate). In summary, this variant meets the criteria to be classified as pathogenic for RPE65-related recessive retinopathy based on the ACMG/AMP criteria applied, as specified by the ClinGen LCA / eoRD VCEP: PS3_Supporting, PM2_Supporting, PM3_Strong, PP1, PP3_Moderate, and PP4_Moderate. (VCEP specifications version 1.0.0; date of approval 09/21/2023).